Previous 10 | Next 10 |
2024-02-07 05:50:15 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular stock jumps after positive interim data for eye disease dru...
2024-02-06 14:00:09 ET Kostas Biliouris from BMO Capital issued a price target of $70.00 for FDMT on 2024-02-06 14:05:00. The adjusted price target was set to $70.00. At the time of the announcement, FDMT was trading at $30.705. The overall price target consensus is at $...
A look at the top 10 most actives in the United States Phunware Inc. (PHUN) rose 19.9% to $0.41 on volume of 260,182,609 shares Palantir Technologies Inc. Class A (PLTR) fell 1.8% to $16.72 on volume of 167,698,349 shares PROSHARES TRUST (SQQQ) rose 0.5% to $11.78 on volume of 155,646,888...
2024-02-06 08:00:00 ET Summary 4D Molecular Therapeutics' gene therapy, 4D-150, shows potential to reduce the treatment burden for patients with severe wet AMD. Interim findings from a Phase 2 trial demonstrate up to an 89% reduction in yearly anti-VEGF injections with 4D-150. ...
2024-02-05 17:40:24 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics Read the full article on Seeking Alpha For further details se...
2024-02-05 16:08:07 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024 4D Molecular stock jumps after positive interim data for eye disease drug Read the full article on Seeking Alpha For further d...
2024-02-05 13:05:53 ET More on Mid-day movers $ stocks. Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade) Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky Peraso Inc. (PRSO) Q3 2023 Earnings Ca...
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is one of today's top gainers. The company's shares have moved -6.32% on the day to $17.49. 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops...
2024-02-05 10:00:03 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...
2024-02-05 08:31:42 ET Chenghe Acquisition ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...
News, Short Squeeze, Breakout and More Instantly...
4D Molecular Therapeutics Inc. Company Name:
FDMT Stock Symbol:
NASDAQ Market:
4D Molecular Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Company") (NASDAQ:FDMT). Investors who purchased 4D Molecular securities are encouraged to obtai...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection rate; 93% of patients received 0 or 1 injection and 77% were injection-free Improvement in mean best corr...